In a report released today, Eliana Merle from Cantor Fitzgerald maintained a Buy rating on ProQR (PRQR), with a price target of $40. The company’s shares opened today at $17.72.
Merle commented:
“We think the company’s RNA-based platform for inherited eye diseases has significant potential. The company established the initial proof of concept for their approach this past September. QR-110, the company’s lead ophthalmology asset, led to meaningful vision improvements in patients with a specific type of inherited blindness called LCA10. The company is applying this approach to many additional genetic eye diseases. For instance, we model peak sales potential of $1.1B for QR-411 which are being studied in other inherited forms of blindness.”
According to TipRanks.com, Merle is a 1-star analyst with an average return of -7.4% and a 9.1% success rate. Merle covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, AnaptysBio Inc, and BioMarin.
ProQR has an analyst consensus of Strong Buy, with a price target consensus of $30.40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24 and a one-year low of $2.80. Currently, ProQR has an average volume of 307.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis.
